Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;15(3):265-72.
doi: 10.4048/jbc.2012.15.3.265. Epub 2012 Sep 28.

Personalized medicine in breast cancer: a systematic review

Sang-Hoon Cho  1 , Jongsu Jeon, Seung Il Kim
Affiliations

Personalized medicine in breast cancer: a systematic review

Sang-Hoon Cho et al. J Breast Cancer. 2012 Sep.

Abstract

The recent advent of "-omics" technologies have heralded a new era of personalized medicine. Personalized medicine is referred to as the ability to segment heterogeneous subsets of patients whose response to a therapeutic intervention within each subset is homogeneous. This new paradigm in healthcare is beginning to affect both research and clinical practice. The key to success in personalized medicine is to uncover molecular biomarkers that drive individual variability in clinical outcomes or drug responses. In this review, we begin with an overview of personalized medicine in breast cancer and illustrate the most encountered statistical approaches in the recent literature tailored for uncovering gene signatures.

Keywords: Biomarker discovery; Breast neoplasms; Individualized medicine; Predictive biomarker; Prognostic biomarker.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Inefficacy of the one-dose-fits-all approach. This figure depicts the percentage of patients for whom a major drug is effective on average. With the high variability across diseases, 38% to 75% of patients fail to respond to a treatment. The average response rate of a cancer drug is the lowest at 25%, suggesting that 75% of patients with cancer are over-dosed and will potentially suffer from an adverse drug reaction. From Spear BB, et al. Trends Mol Med 2001;7:201-4 [1].
Figure 2
Figure 2
Schematic plot for a systematic statistical approach to identify predictive biomarkers.
Figure 3
Figure 3
Cost of sequencing a human-sized genome. Note that a logarithmic scale is used on the Y axis. The cost of sequencing rapidly decreased at an exponential rate from 2001 to 2007. The sudden drop in cost around January 2008 was due to sequencing technology geared up from the first generation ("Sanger-based" or dideoxy chain termination sequencing) to the second generation (or "next-generation"). The cost of sequencing has dramatically decreased since 2008. From Wetterstrand KA. DNA sequencing costs: data from the NHGRI large-scale genome sequencing program. http://www.genome.gov/sequencingcosts/ [81].
See this image and copyright information in PMC

References

    1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7:201–204. - PubMed
    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205. - PubMed
    1. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301–306. - PubMed
    1. President's Council of Advisors on Science and Technolgy. Priorities for Personalized Medicine. Washington, DC: President's Council of Advisors on Science and Technolgy; 2008.
    1. Pfizer. Think Science Now Perspective. Approaches to Cancer Care: the Promise of Personalized Medicine. New York: Pfizer; 2010.